Skip to main content


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

News

Dr. Reddy’s Wins Big at “Express Pharma Excellence Awards 2025”

Dr. Reddy’s Wins Big at “Express Pharma Excellence Awards 2025”
Dr. Reddy’s Wins Big at “Express Pharma Excellence Awards 2025”
 

We are thrilled to announce that Dr. Reddy's Laboratories has been honored with multiple accolades at the Express Pharma Excellence Awards 2025. These prestigious awards recognize our excellence in three key categories:

  1. Export Powerhouse (FY24) Finished Formulations: Celebrating our global reach and impact in delivering high-quality finished pharmaceutical products.
  2. Market Trailblazers: Acknowledging our innovative strategies and leadership in the pharmaceutical market.
  3. Export Powerhouse (FY24) APIs & Intermediates: Highlighting our strength in exporting active pharmaceutical ingredients and intermediates worldwide.

These awards are a testament to our unwavering commitment to innovation, quality, and excellence in the pharmaceutical industry. We are incredibly proud of our dedicated team whose hard work and passion have made these achievements possible. Thank you to @Express Pharma for recognizing our efforts and to our partners, customers, and stakeholders for their continuous support. Together, we are making a difference in global healthcare.

Contact Us

Please fill in the following form and we'll get back to you shortly.

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.